Overview
In the management of pancreatic head adenocarcinoma, the OncoSil™-supported multidisciplinary model represents a cutting-edge therapeutic integration. This approach combines standard-of-care treatments—such as surgery, chemotherapy, and external beam radiotherapy—with OncoSil™, a localized brachytherapy micro-implant.
OncoSil™ consists of radioactive Phosphorus-32 (P-32) micro-particles administered directly into the tumor. The primary objective is to deliver a concentrated dose of radiation to reduce tumor volume, potentially converting unresectable cases into surgical candidates while minimizing damage to adjacent healthy organs.
The Clinical Objective
Surgical resection is currently the only curative path for pancreatic cancer. However, the prognosis remains challenging due to late-stage diagnoses:
- Localized Disease: ~44% 5-year survival.
- Regional Spread: ~16% 5-year survival.
- Distant Metastasis: ~3% 5-year survival.
- Overall Average: ~13%.
Approximately 80% of pancreatic head cancers are unresectable at the time of discovery. Many are classified as Borderline Resectable due to their proximity to major vascular structures (e.g., the portal vein or superior mesenteric artery).
The Role of Neoadjuvant OncoSil™:
By integrating localized P-32 internal radiation with systemic chemotherapy, we aim to:
- Increase the probability of achieving an R0 Resection (complete tumor removal with clear margins).
- Extend disease-free and overall survival.
- Provide a targeted radiation alternative that avoids the collateral tissue damage often seen with External Beam Radiation Therapy (EBRT).
Technical Specifications: Phosphorus-32 (P-32)
- Half-life: 14.27 days.
- Radiation Delivery: 98% of the therapeutic dose is absorbed within the target tissue over 81 days.
- Administration: Delivered via Endoscopic Ultrasound (EUS) or direct intraoperative injection.
The Multidisciplinary Framework
| Phase | Description |
| 1. Expert Evaluation | Review by a dedicated Tumor Board including Surgeons, Medical Oncologists, Nuclear Medicine specialists, and Gastroenterologists. |
| 2. OncoSil™ Implantation | Intratumoral injection of P-32 microspheres, typically under general anesthesia via EUS. |
| 3. Systemic Synergy | Administration of standard chemotherapy (e.g., FOLFIRINOX or Nab-paclitaxel + Gemcitabine) to attack systemic micrometastases. |
| 4. Surgical Re-assessment | Comprehensive re-staging (PET/CT, MRI, tumor markers) after a minimum of 3 months to evaluate candidates for curative surgery. |
Patient Eligibility Criteria
Who is a Candidate?
- Confirmed pancreatic head adenocarcinoma.
- Borderline resectable or locally advanced (unresectable) tumors.
- Age ≥18 with a Karnofsky Performance Score ≥70.
- Patients capable of tolerating intensive chemotherapy (FOLFIRINOX).
- Applicable in recurrent cases for palliative local control.
Who is Not Eligible?
- Evidence of distant metastases (Stage IV).
- Tumors involving multiple anatomical regions of the pancreas.
- Anatomical barriers preventing safe endoscopic access.
- Pregnancy, breastfeeding, or severe comorbidities.
- History of other malignancies within the last 5 years.
Why Choose This Model?
- Precision: Targeted radiation spares the stomach, liver, and kidneys.
- Synergy: Localized P-32 works in tandem with systemic chemotherapy to maximize tumor shrinkage.
- Expertise: Our center features high-volume expertise in Hepatopancreatobiliary (HPB) surgery and liver transplantation.
- Speed: Rapid, coordinated decision-making ensures treatment begins without delay.
Frequently Asked Questions (FAQ)
What are the side effects of OncoSil™?
Side effects are generally related to the injection procedure and are localized. Patients may experience temporary abdominal pain, fatigue, nausea, or mild gastrointestinal discomfort (reflux). These symptoms are typically short-lived and manageable with standard supportive care.
Can OncoSil™ be used alongside other treatments?
Absolutely. OncoSil™ is designed to be part of a multimodal plan. It is typically administered during the “rest week” of a chemotherapy cycle. Clinical data indicates it is safe to use with both FOLFIRINOX and Gemcitabine-based regimens.
Is the radioactive material permanent?
The micro-particles remain permanently within the tumor tissue; however, the radioactivity decays over time. Because P-32 is a pure beta-emitter with a short range, the residual radiation does not pose a risk to the patient’s family, the public, or the environment.
How is the OncoSil™ procedure performed?
The implantation is typically performed via Endoscopic Ultrasound (EUS) while the patient is under general anesthesia or deep sedation. A specialized gastroenterologist uses a fine needle to inject the P-32 microspheres directly into the pancreatic tumor. Because it is performed endoscopically (through the mouth and stomach), there are usually no external incisions, leading to a faster recovery compared to traditional surgery.
How long is the recovery period after the injection?
Most patients can return home the same day or the following morning. Since the procedure is minimally invasive, physical recovery is rapid. You may experience mild soreness or “fullness” in the upper abdomen for 2–3 days, but this rarely interferes with the continuation of your scheduled chemotherapy.
Does OncoSil™ replace the need for surgery?
No, OncoSil™ is not a replacement for surgery; it is a bridge to surgery. The primary goal is “downstaging”—shrinking a tumor that was previously too dangerous to remove so that a surgeon can later perform a successful R0 resection. If the tumor does not shrink enough for surgery, OncoSil™ still serves as a powerful tool for local disease control.
Is there a risk of radiation “leaking” to other organs?
The P-32 microspheres are designed to be biocompatible and non-resorbable, meaning they stay exactly where they are injected. Because Phosphorus-32 emits beta radiation—which travels only a few millimeters in tissue—the radiation remains concentrated within the tumor, leaving the surrounding healthy organs like the stomach, liver, and kidneys largely unaffected.
What happens if the tumor cannot be surgically removed after OncoSil™?
In cases where the tumor remains unresectable (locally advanced), OncoSil™ still provides significant value as a palliative treatment. It can help control the growth of the primary tumor, reduce pain associated with tumor pressure on local nerves, and potentially extend survival when combined with ongoing systemic chemotherapy
Departments
Related Videos
Our Doctors
News
